Fovea Pharmaceuticals SA
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private, Subsidiary
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://www.fovea-pharma.com
Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
Phase 2
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: 2304 Eye Drops High DoseDrug: 2304 Eye Drops Low DoseDrug: Placebo Eye Drops
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Fovea Pharmaceuticals SA
- Target Recruit Count
- 267
- Registration Number
- NCT01319487
- Locations
- 🇺🇸
Center 1115, Phoenix, Arizona, United States
🇺🇸Center 1116, Phoenix, Arizona, United States
🇺🇸Center 1108, Fort Myers, Florida, United States
Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis
Phase 2
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Fovea Pharmaceuticals SA
- Target Recruit Count
- 716
- Registration Number
- NCT01120132
- Locations
- 🇺🇸
ORA, Andover, Massachusetts, United States
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
Phase 1
Terminated
- Conditions
- Macular EdemaCentral Retinal Vein Occlusion
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- Fovea Pharmaceuticals SA
- Target Recruit Count
- 11
- Registration Number
- NCT00969293
- Locations
- 🇫🇷
CHU d'Amiens, Centre Saint-Victor, Amiens, France
🇫🇷Centre Intercommunal de Creteil, Creteil, France
🇫🇷CHU de Dijon, Hôpital Général, Dijon, France
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
Phase 2
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Fovea Pharmaceuticals SA
- Target Recruit Count
- 155
- Registration Number
- NCT00833495
- Locations
- 🇺🇸
Ora, Andover, Massachusetts, United States